To address whether the altered inflammatory and FAP response activated by acute injury is directly responsible for impaired regeneration seen in juvenile D2-mdx muscle, we employed the anti-inflammatory glucocorticoid (GC), deflazacort, which is widely prescribed to the DMD patients. The gene discussed is FAP; the disease is Duchenne muscular dystrophy.